Apa sebenarnya pembatasan PFAS UE itu?, dan di mana posisi sebenarnya saat ini?
<figure class="blog-chart" style="max-width:640piksel;batas:1.5rem otomatis;ukuran font:12piksel;tinggi garis:1.3;warna:inherit"> <svg viewBox="0 0 560 380" style="max-width: 100%; height: auto; font-family: 'Inter', system-ui, sans-serif; warna: #1e293b; --chart-muted: #64748b;" role="img" aria-labelledby="proposed-pfas-concentration-limits-title proposed-pfas-concentration-limits-desc"> <style> /* The renderer puts the chart in an iframe whose element background is black, and the iframe is a different shape to the chart, so the letterbox bands showed as black frames around it (prod 09-22). The document inside the iframe is transparent by default; painting it here covers the element background, and when the chart is inlined instead this matches nothing. Keep angle brackets out of this block: a style element inside an SVG is parsed as foreign content, so one stray bracket discards every rule in it. */ html, body { background: #ffffff; batas: 0; } @media (prefers-reduced-motion: reduce) { * { animation: none !important; transition: none !important; } } </style> <rect x="0" y="0" width="560" height="380" rx="8" fill="#ffffff" /> <title id="proposed-pfas-concentration-limits-title">Proposed PFAS concentration limits</title> <desc id="proposed-pfas-concentration-limits-desc">Proposed PFAS concentration limits: values for Individual PFAS, Sum of PFAS, Total incl. polymers. Proposed PFAS concentration limits. data batang horizontal: Individual PFAS 25; Sum of PFAS 250; Total incl. polymers 50000.Source: Keller & Heckman, Annex XV restriction proposal 2023-02.</desc> <text x="280.0" y="29" text-anchor="middle" font-size="18" font-weight="800" fill="currentColor">Proposed PFAS concentration limits</text> <line x1="145" y1="298.0" x2="510" y2="298.0" stroke="currentColor" opacity="0.08" /> <line x1="145" y1="243.0" x2="510" y2="243.0" stroke="currentColor" opacity="0.08" /> <line x1="145" y1="188.0" x2="510" y2="188.0" stroke="currentColor" opacity="0.08" /> <line x1="145" y1="133.0" x2="510" y2="133.0" stroke="currentColor" opacity="0.08" /> <line x1="145" y1="78.0" x2="510" y2="78.0" stroke="currentColor" opacity="0.08" /> <text x="136.0" y="122.2" text-anchor="end" font-size="11" fill="currentColor" opacity="0.8"><tspan x="136.0" dy="0">Individual PFAS</tspan></text> <rect x="145" y="78.0" width="0.2" height="68.0" rx="4" fill="#f97316" /> <text x="153.2" y="122.2" font-size="11" fill="currentColor">25</text> <text x="136.0" y="198.2" text-anchor="end" font-size="11" fill="currentColor" opacity="0.8"><tspan x="136.0" dy="0">Sum of PFAS</tspan></text> <rect x="145" y="154.0" width="1.8" height="68.0" rx="4" fill="#38bdf8" /> <text x="154.8" y="198.2" font-size="11" fill="currentColor">250</text> <text x="136.0" y="274.2" text-anchor="end" font-size="11" fill="currentColor" opacity="0.8"><tspan x="136.0" dy="0">Total incl.</tspan><tspan x="136.0" dy="12">polymers</tspan></text> <rect x="145" y="230.0" width="365.0" height="68.0" rx="4" fill="#a78bfa" /> <text x="518.0" y="274.2" font-size="11" fill="currentColor">50000</text> <text x="280.0" y="366" text-anchor="middle" font-size="10" fill="var(--chart-muted, currentColor)">Sumber: Keller & Heckman, Annex XV restriction proposal (2023-02)</text> </svg> </figure>
The EU PFAS restriction 2027 timeline is a proposal under REACH, not a law in force, and the process still has at least one full committee stage to run. A REACH restriction is an amendment to Annex XVII of the regulation that limits or bans the manufacture, use and placing on the market of a substance; a derogation is a named exemption from that restriction, usually time-limited and conditional; and a RAC or SEAC opinion is the formal advice the European Chemicals Agency’s committees give before the Commission and Member States decide. The proposal, prepared by the authorities of Denmark, Germany, the Netherlands, Norway and Sweden, covers some 10,000 compounds, both non-polymers and polymers, and builds on the OECD definition (the European Parliament’s own briefing on the restriction, 2026).
The committee stage has now produced two opinions. RAC adopted its opinion in early March 2026 and SEAC agreed its draft opinion in March 2026; both committees support the restriction as the most appropriate regulatory measure (the European Parliament’s own briefing on the restriction, 2026). The stakeholder consultation on SEAC’s draft ran from 26 March to 25 Mungkin 2026 and drew over 3,500 contributions, with SEAC planning to adopt its final opinion by the end of 2026.
What happens after that is where the sources diverge in precision. Counsel reading the process in March 2026 put Commission adoption no earlier than the third quarter of 2027, with restrictions not applying before 2029 (the timeline as counsel read it in March 2026). That is a law firm’s assessment of the process, not a Commission statement. The Commission’s own record shows a steady sequence of earlier PFAS restrictions, from the PFOS ban in 2006 through the second-round PFCA restriction in 2026, and confirms that national authorities asked ECHA to restrict all PFAS in March 2023 (the Commission’s own record of earlier PFAS restrictions, accessed 2026). Firefighting foams sit under a separate restriction, not this one.
Why the thresholds matter more than the ban
The operative risk for a lab is not the word “ban.” It is the concentration limit and the total-fluorine trigger underneath it. The proposal sets 25 ppb for any individual PFAS by targeted analysis, 250 ppb for the sum of PFAS, Dan 50 ppm for PFAS including polymeric PFAS (the proposal’s concentration limits, 2023). Separately, if total fluorine exceeds 50 mg F/kg, pabrikan, importer or downstream user must on request provide enforcement authorities proof that the fluorine is PFAS or non-PFAS.
Those numbers are proposed, not in force, and RAC itself flagged that the 25 ppb limit may not currently be achievable for certain PFAS with available analytical methods, while recommending sample degradation be required for the 250 ppb sum limit (RAC’s own reservations about the analytical limits, 2026). The derogation structure is time-limited, use-specific and conditional rather than a single number: the briefing describes a general 18-month transition with mostly time-limited derogations of 5 atau 12 years, while the proposal summary states the time-limited derogations as 6.5 Dan 13.5 years from entry into force. Treat the duration as unsettled and plan around the structure.
Why are environmental groups acting before the law is final, and what does that change for a laboratory?
Because the exposure reaches companies through legal and commercial channels on their own timetable, not through the regulation’s. In October 2026, ClientEarth, Générations Futures and Notre Affaire à Tous put Groupe SEB, the owner of Tefal, on notice under the French duty-of-vigilance law, demanding a public commitment to transition away from PFAS within three months or face a lawsuit in the Paris Judicial Court (the legal notice served on Groupe SEB, 2026). It is a notice, not a lawsuit; a suit may follow.
<figure class="blog-chart" style="max-width:640piksel;batas:1.5rem otomatis;ukuran font:12piksel;tinggi garis:1.3;warna:inherit"> <svg viewBox="0 0 560 380" style="max-width: 100%; height: auto; font-family: 'Inter', system-ui, sans-serif; warna: #1e293b; --chart-muted: #64748b;" role="img" aria-labelledby="pfas-restriction-milestones-title pfas-restriction-milestones-desc"> <style> /* The renderer puts the chart in an iframe whose element background is black, and the iframe is a different shape to the chart, so the letterbox bands showed as black frames around it (prod 09-22). The document inside the iframe is transparent by default; painting it here covers the element background, and when the chart is inlined instead this matches nothing. Keep angle brackets out of this block: a style element inside an SVG is parsed as foreign content, so one stray bracket discards every rule in it. */ html, body { background: #ffffff; batas: 0; } @media (prefers-reduced-motion: reduce) { * { animation: none !important; transition: none !important; } } </style> <rect x="0" y="0" width="560" height="380" rx="8" fill="#ffffff" /> <title id="pfas-restriction-milestones-title">PFAS restriction milestones</title> <desc id="pfas-restriction-milestones-desc">PFAS restriction milestones: values for RAC opinion, SEAC draft opinion, SEAC final opinion. PFAS restriction milestones. data lolipop: RAC opinion 2026.17; SEAC draft opinion 2026.23; SEAC final opinion 2026.99.Source: White & Case, RAC opinion alert 2026.</desc> <text x="280.0" y="29" text-anchor="middle" font-size="18" font-weight="800" fill="currentColor">PFAS restriction milestones</text> <line x1="145" y1="298.0" x2="510" y2="298.0" stroke="currentColor" opacity="0.08" /> <line x1="145" y1="243.0" x2="510" y2="243.0" stroke="currentColor" opacity="0.08" /> <line x1="145" y1="188.0" x2="510" y2="188.0" stroke="currentColor" opacity="0.08" /> <line x1="145" y1="133.0" x2="510" y2="133.0" stroke="currentColor" opacity="0.08" /> <line x1="145" y1="78.0" x2="510" y2="78.0" stroke="currentColor" opacity="0.08" /> <text x="136.0" y="118.7" text-anchor="end" font-size="11" fill="currentColor" opacity="0.8"><tspan x="136.0" dy="0">RAC opinion</tspan></text> <line x1="145" y1="114.7" x2="509.9" y2="114.7" stroke="currentColor" opacity="0.15" stroke-width="1" /> <circle cx="509.9" cy="114.7" r="6" fill="#f97316" /> <text x="521.9" y="118.7" font-size="11" fill="currentColor">2026.17</text> <text x="136.0" y="192.0" text-anchor="end" font-size="11" fill="currentColor" opacity="0.8"><tspan x="136.0" dy="0">SEAC draft</tspan><tspan x="136.0" dy="12">opinion</tspan></text> <line x1="145" y1="188.0" x2="509.9" y2="188.0" stroke="currentColor" opacity="0.15" stroke-width="1" /> <circle cx="509.9" cy="188.0" r="6" fill="#38bdf8" /> <text x="521.9" y="192.0" font-size="11" fill="currentColor">2026.23</text> <text x="136.0" y="265.3" text-anchor="end" font-size="11" fill="currentColor" opacity="0.8"><tspan x="136.0" dy="0">SEAC final</tspan><tspan x="136.0" dy="12">opinion</tspan></text> <line x1="145" y1="261.3" x2="510.0" y2="261.3" stroke="currentColor" opacity="0.15" stroke-width="1" /> <circle cx="510.0" cy="261.3" r="6" fill="#a78bfa" /> <text x="522.0" y="265.3" font-size="11" fill="currentColor">2026.99</text> <text x="280.0" y="366" text-anchor="middle" font-size="10" fill="var(--chart-muted, currentColor)">Sumber: White & Case, RAC opinion alert (2026)</text> </svg> </figure>
Produsen Peptida Sintetis The NGOs’ argument is that SEB’s vigilance plan identifies PTFE as safe, which they say fails to recognise the risks it poses; ClientEarth’s stated position is that the demand is to plan the transition, not to transition immediately (the legal notice served on Groupe SEB, 2026). For a laboratory, the relevant pattern is who gets named. PFAS litigation defendants have expanded from primary manufacturers to companies that treated products with PFAS and to supply-chain companies that assemble products from PFAS-treated components without using the chemicals themselves (how PFAS litigation reaches downstream users, diambil 2026).
Where does fluorinated chemistry actually enter peptide synthesis, purification and QC?
PFAS restriction peptide synthesis questions become answerable once you stop thinking in product categories and start naming components. Fluoropolymers used in pharma manufacturing include PFA, PTFE, FEP, TFM, ETFE, PCTFE and PVDF, appearing in mechanical seals, valve seats, gaskets, O-rings, lined pipework and hoses, scrubber linings and flexible flow-reactor tubing; QC analysis depends on fluoropolymers in HPLC, GC and NMR instrumentation (EFPIA’s inventory of fluoropolymer uses, EFPIA submission). That inventory is a trade-association submission, not a neutral technical source, but the component list is specific enough to walk a plant with.
The single-use side is broader still. Fluoropolymer-containing bioprocessing components include liquid and gas filtration membranes and devices, gaskets and seals, fittings, bags, tubing clamps, pump parts, valves, mixer parts, tubing, laboratory QC consumables, and bags for cell culture and cryostorage, with PTFE, PVDF, FKM and PFA the common types (BPSA’s list of single-use components, 2023). PVDF membranes are widely used for sterilising-grade filtration and may fall within PFAS definitions (a supplier’s own account of PVDF membranes, vendor white paper). On the reagent side, TFA is widely employed as an ion-pairing reagent in reversed-phase liquid chromatography for both purification and analytical characterisation of peptides, and residual TFA- can shield peptide polarity, increasing retention time and lipophilicity (TFA’s dual role in peptide purification and analysis, 2025).
What is the difference between product exposure and process exposure, and why does it decide which records matter?
Separate potential product contact or carryover from equipment and environmental uses when building an inventory. A process aid cannot be assumed never to enter the product without an appropriate assessment. These are practical inventory categories, not substitutes for the legal definitions or scope of a restriction.
The measured evidence on carryover is thinner than the concern. One aqueous leaching study of fluoropolymer tubing detected TFA, PFPrA and PFBA, with TFA highest in FEP at 121 ± 96 ng/g and in PFA1 at 34.6 ± 11.6 ng/g, PFBA in PTFE1 at 175 ± 298 ng/g, and PFOA at 22 ke 24 ng/g in PTFE1, PTFE2 and PFA1; non-fluorinated polymers including PVC, PP and PEEK were not PFCA-free (the tubing-leaching measurements, York University study). Those are one study’s measurements with wide error bars, not an industry benchmark, and no source in this set gives a measured PFAS concentration in a peptide-specific consumable such as a resin, vessel or filter used in solid-phase synthesis.
The record consequence of getting the split wrong
Green Peptide Synthesis A certificate of analysis cannot evidence a wetted part. A CoA describes the material you bought or the peptide you released; it says nothing about what a seal in the flow path released into a solvent stream over a campaign. If you classify a fluorinated component as process exposure and file it under equipment maintenance, you will have no analytical record when a customer asks whether that component can shed into the product. If you classify it as product exposure, you inherit a testing obligation you may not be able to meet with current methods.
That asymmetry is why the analytical method you choose determines what you can claim. Total fluorine includes both inorganic and organic fluorine; extractable organofluorine is the organic fluorine recovered by extraction and measured by combustion ion chromatography; and targeted LC-MS/MS is Peptide Information the gold standard for known PFAS but captures only a narrow subset, with US EPA method 1633A targeting only 40 PFAS and limited retention for ultrashort-chain PFAS (the limits of each analytical method, 2026).
How can a lab tell intentional PFAS use from contamination or trace carryover?
You cannot tell them apart from a single positive fluorine result, and the methods that produce that result were not designed to make the distinction. EPA Method 1621 estimates adsorbable organic fluorine by combustion ion chromatography, measuring organofluorine from PFAS and non-PFAS fluorinated compounds retained on at least 80 mg of granular activated carbon, and reports results as fluoride concentration; it is a method-defined parameter, with poor retention of short-chain compounds under four carbons and low recoveries for long-chain hydrophobic compounds over eight carbons (EPA Method 1621, 2024). The method document states plainly that it is not approved for Clean Water Act compliance monitoring until promulgated through rulemaking, and a January 2025 proposed rule would add it and its AOF parameter to 40 CFR part 136 (itu 2025 proposed rule adding Method 1621 ke 40 CFR part 136, 2025).
The practical consequence is that a positive total-fluorine or AOF result tells you fluorine is present, not where it came from. Combustion ion chromatography for extractable organofluorine has a limit of detection set at the lowest calibration sample, 50 ng/mL F injected, with an average background signal of 65 ng/mL F at 17% RSD, and combustion efficiencies of 13 PFAS ranging from 66% ke 110% rather than 100%; the method also cannot differentiate Hobt Peptide Synthesis inorganic from organic fluorine, so extraction must remove inorganic fluoride first (combustion ion chromatography for extractable organofluorine, 2021). The gap between measured EOF and the fluorine accounted for by measured PFAS is termed unidentified organofluorine, and it is the space where contamination, carryover and unlisted fluorinated species all sit. Produsen Peptida Khusus
What must a supplier declaration, SDS, CoA and analytical method record actually contain to be defensible?
PFAS supplier declarations laboratory teams can actually defend are built from four record types that answer four different questions, and each has a failure mode when it is treated as a substitute for the others. A supplier declaration should state whether PFAS are intentionally added, name the CAS numbers and the function of each, identify the affected sites and articles, and reference the supporting SDS and test reports. An SDS Section 3 composition entry is the supplier’s own regulatory statement and is only as good as the supplier’s knowledge of its own supply chain. A CoA evidences the batch you received against the specification you agreed. An analytical method record documents what was measured, by which method, with what detection limit and what recovery.
The defensibility problem is that these records are governed by data-integrity expectations that predate PFAS entirely. The WHO data integrity guideline defines ALCOA+ as attributable, terbaca, sejaman, original and accurate, with additional emphasis on being complete, konsisten, enduring and available throughout the data life cycle for the defined retention period, and it directs that where a system cannot support ALCOA+ by design, such as legacy systems with no audit trail, mitigation measures be taken for defined temporary periods (the WHO data integrity guideline, WHO TRS 1033 Annex 4). For electronic records, 21 CFR 11.10(e) requires secure, computer-generated, time-stamped audit trails that independently record the date and time of operator entries and actions creating, modifying or deleting electronic records, with changes not obscuring previously recorded information and audit trail documentation retained at least as long as the subject records (21 CFR 11.10(e), current eCFR). Neither source connects to PFAS monitoring directly; they apply because the records you are building are GxP records.
What does a team do when a fluorinated material has no qualified alternative yet?
You document continued use and qualify an alternative in parallel, because the regulation’s own structure assumes both will happen at once. The pharmaceutical industry’s position is that PFAS materials are essential for manufacturing processes, medicinal products, APIs, delivery devices and packaging, that medicines and components cannot be substituted one-to-one without R&D, legal and regulatory approval, and it has sought a time-unlimited derogation (the pharmaceutical industry’s response to the opinions, 2026). That is an industry position, not a regulator finding, and it should be read as one.
The substitution problem is real at the reagent level too. The ACS Green Chemistry Institute Pharmaceutical Roundtable’s 2026 call for TFA replacements seeks alternatives that mimic TFA’s efficacy in cleaving common acid-sensitive protecting groups and in UPLC purification while retaining its resolving power, and references ultra-low loadings for cleavage operations, implying current usage sits at higher, non-catalytic levels (the ACS GCIPR call for TFA replacements, 2026). TFA is under regulatory scrutiny, not banned.
Pertanyaan yang Sering Diajukan
Does the EU PFAS restriction apply to a peptide API itself?
The proposed exclusion for PFAS used as active substances in human or veterinary medicinal products is specific to the broader restriction proposal. It does not exempt all pharmaceutical materials or override existing controls. Excipients, peralatan, packaging and process aids need their own assessment. In Vitro Peptide Synthesis
Is a fluorinated building block an article or a mixture?
A supplied building block may be a substance or a mixture, depending on composition; a defined chemical substance is not a mixture merely because it is supplied in a bottle. The REACH article definition depends on the object’s function and its shape, surface or design. Obtain the supplier’s classification rationale for the actual material.
How long does a lab realistically have before records are requested?
Longer than the headlines suggest, but not long enough to postpone the inventory. Commission adoption is expected no earlier than the third quarter of 2027, and restrictions would not apply before 2029 (European Parliamentary Research Service briefing, 2026). The practical deadline is earlier than the legal one: customers, auditors and tender questionnaires tend to ask for material declarations years before a restriction bites, and an inventory assembled under that pressure is the one that ends up incomplete.
Does switching to a non-fluorinated membrane require method revalidation?
A membrane substitution needs a documented change assessment. Evaluate product contact, extractables and leachables, recovery, adsorption and process performance. The evidence may justify targeted studies or broader revalidation; neither a full rerun nor a larger burden is automatic.
Kesimpulan
The decision rule for this quarter is simple: if you cannot name the fluorinated component, the polymer it is made from, and whether it touches the product, you cannot answer the questionnaire that has already arrived. Start the inventory at the component level, using the EFPIA and BPSA lists as walk-down checklists rather than as scope definitions, and record each item against the four fields that make a declaration defensible: intentionally added status, CAS number, function, and affected site or article.
Then apply the product-versus-process split before you write anything down. Components that touch the product or ship inside an article need an analytical record and a method that states its own detection limit and recovery. Components that never touch the product need a documented continued-use justification and a parallel qualification track, because the derogation structure assumes both exist at once. The regulation is not final, and the thresholds may move, but the inventory and the record fields will not change shape when they do.
Tentang penerbit. MOL Changes is a peptide research and development organisation that offers custom peptide synthesis, modification services and peptide testing such as MS, HPLC, pH, kemurnian, content and endotoxin. It therefore has a commercial interest in peptide manufacturing, and readers should weigh its perspective on this topic accordingly. The guidance above does not depend on its products or services.
